TCGA-OR-A5J9-01
Adrenocortical Carcinoma · Adrenocortical Carcinoma · Adrenocortical Carcinoma, Usual Type
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.535
- TGF_BETA_SIGNALING+0.419
- HEDGEHOG_SIGNALING+0.413
- NOTCH_SIGNALING+0.375
- MYC_TARGETS_V2+0.322
- PANCREAS_BETA_CELLS+0.313
- ANGIOGENESIS+0.233
- UV_RESPONSE_DN+0.124
- APICAL_SURFACE+0.079
- UNFOLDED_PROTEIN_RESPONSE+0.048
Top 10 suppressed
- INTERFERON_GAMMA_RESPONSE-0.455
- INTERFERON_ALPHA_RESPONSE-0.430
- IL6_JAK_STAT3_SIGNALING-0.419
- ALLOGRAFT_REJECTION-0.329
- INFLAMMATORY_RESPONSE-0.285
- MTORC1_SIGNALING-0.282
- GLYCOLYSIS-0.267
- FATTY_ACID_METABOLISM-0.256
- XENOBIOTIC_METABOLISM-0.239
- OXIDATIVE_PHOSPHORYLATION-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 0d373d8e-2507-4d88-8e19-d3f7b66955b4 | — | — | 0.796 |
| 2 | 4e24bc58-d246-4c96-952a-a18f95d142b2 | — | — | 0.795 |
| 3 | ERR2598104 | fetal | fetal | 0.788 |
| 4 | TCGA-A1-A0SB-01A-11R-A144-07 | — | A | 0.784 |
| 5 | 20ed86b0-2e3d-44ec-88cd-eac5486fe15c | — | — | 0.772 |
| 6 | SRR17866827 | — | — | 0.763 |
| 7 | 4ce20929-7d04-4c4b-9e3c-de22d237f254 | — | — | 0.759 |
| 8 | AUR-AD9E-TTM2-A-1-1-R-A542-39 | — | B | 0.753 |
| 9 | 9a38d0dc-6b2c-439d-b10e-efd0f1cba209 | — | — | 0.753 |
| 10 | ca7940e6-af7e-44fd-a6fc-5d86dc1d86c4 | — | — | 0.746 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.535 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.419 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.413 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.375 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.322 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.313 | Cobimetinib | — uncovered |
| ANGIOGENESIS | 0.233 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.124 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.079 | Temsirolimus | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.048 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.037 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.020 | Inavolisib | — uncovered |
| MYOGENESIS | 0.008 | Inavolisib | — uncovered |